论文部分内容阅读
目的研究培美曲赛单药治疗复发、转移的晚期非小细胞肺癌患者的疗效和安全性。方法 35例既往化疗失败的晚期非小细胞肺癌患者,应用培美曲赛500mg/m2治疗;结果35例患者的有效率为14.29%。中位疾病进展时间(TIP)为5.2个月。培美曲塞的不良反应主要表现为轻度恶心、呕吐、乏力,Ⅲ～Ⅳ度中性粒细胞减少的发生率较低.。结论晚期非小细胞肺癌患者的二线化疗,应用培美曲赛单药进行化疗的疗效满意且不良反应较低,耐受性好。
Objective To study the efficacy and safety of pemetrexed monotherapy in the treatment of relapsed and metastatic advanced non-small cell lung cancer patients. Methods 35 patients with advanced non-small cell lung cancer who had failed previous chemotherapy were treated with Pemetrexed 500mg / m2. The results showed that the effective rate of 35 patients was 14.29%. Median disease progression time (TIP) was 5.2 months. Pemetrexed adverse reactions mainly manifested as mild nausea, vomiting, fatigue, Ⅲ ~ Ⅳ neutropenia lower incidence. Conclusions Second-line chemotherapy in patients with advanced non-small cell lung cancer, the use of pemetrexed single-agent chemotherapy with satisfactory efficacy and adverse reactions lower, well tolerated.